Drug Discovery

Neurotrope signs licensing deal for accelerated synthesis of Alzheimer’s drug Bryostatin-1

Neurotrope has signed a licensing agreement with Stanford University for an accelerated synthesis of Alzheimer's drug bryostatin-1.

Biscayne Neurotherapeutics raises $3m for antiepileptic compound

Biscayne Pharmaceuticals has raised financing for its new spin-out, Biscayne Neurotherapeutics, which was recently established to develop its biopharmaceutical assets for the treatment of neurological disorders.

Cellestia Biotech raises CHF8m seed financing

Cellestia Biotech has raised CHF8m in funding from private investors and PPF Group to advance its lead anti-cancer compound CB-103 to clinical development stage.

Connect secures $25m financing to advance immune modulators clinical development

Connect Biopharmaceuticals has completed a $20m Series A financing to advance clinical development of novel immune modulators.

Discuva secures Innovate UK grant for new antibiotics development

Innovate UK has awarded a £1.5m Biomedical Catalyst early-stage award to drug discovery firm Discuva for the development of novel antibiotics to tackle the issue of multidrug-resistance and life-threatening bacterial infections.

Cue Biopharma raises $26M in funding

Cue Biopharma has announced a total of $26m of invested private capital, led by MDB Capital Group, to develop next-generation biologics to selectively control T Cell activity.

ELC Group partners with PSR Group for advanced drug development

Global life sciences partner ELC Group is collaborating with New Zealand-based research and development firm Pharma Scientific Research (PSR Group) to create highly advanced products for the pharmaceutical market.

Intrexon to buy clinical-stage gene delivery firm GenVec

Intrexon has agreed to acquire clinical-stage company GenVec which has developed the AdenoVerse gene delivery technology.

aTyr Pharma’s Resolaris secures FDA fast track status

The US Food and Drug Administration (FDA) has granted Fast Track designation for aTyr Pharma's Resolaris to treat limb girdle muscular dystrophy 2B (LGMD2B).